Tresiba Sexual Function Impact: What the Evidence Actually Shows

Does Tresiba Directly Cause Sexual Side Effects?

Insulin degludec carries no FDA-labeled sexual side effects. The prescribing information does not list erectile dysfunction, decreased libido, dyspareunia, or orgasmic difficulty among adverse reactions. Any link between Tresiba and sexual function runs through the indirect pathways that connect overall glycemic control to reproductive endocrinology, not through a receptor-level drug action on gonadal tissue.

That distinction matters clinically. A patient reporting new-onset sexual dysfunction after starting degludec is far more likely experiencing the residual effects of years of suboptimal glycemic control than a drug-specific effect. Switching to degludec may actually improve that picture over time.

Why Glycemic Control and Sexual Function Are Linked

Chronic hyperglycemia damages autonomic nerve fibers and endothelial cells through advanced glycation end-product accumulation and oxidative stress. In men, this produces diabetic autonomic neuropathy that impairs penile vascular and neural responses. A 2021 meta-analysis in the Journal of Sexual Medicine (N=145,000 across 145 studies) found that men with type 2 diabetes carry a 3.5-fold higher prevalence of erectile dysfunction compared with normoglycemic controls (1).

In women, diabetic neuropathy reduces genital sensation and vaginal lubrication. The 2020 American Diabetes Association Standards of Care explicitly acknowledge sexual dysfunction as a microvascular and neuropathic complication that clinicians should screen for annually (2).

The Hypoglycemia-to-Hormone Axis

Hypoglycemic episodes, especially nocturnal ones, activate the hypothalamic-pituitary-adrenal axis acutely. Cortisol and epinephrine surge within minutes of glucose dropping below 70 mg/dL. Repeated activation suppresses gonadotropin-releasing hormone pulsatility, which in turn reduces LH, FSH, testosterone, and estradiol over time (3). Sleep architecture also fragments during nocturnal hypoglycemia, and testosterone secretion is tightly coupled to slow-wave sleep (4). Fewer hypoglycemic awakenings means less cortisol-mediated androgen suppression.

DEVOTE Trial: The Core Evidence Base

The DEVOTE trial (N=7,637, median follow-up 2.0 years) was a double-blind, treat-to-target, cardiovascular outcomes trial that randomized adults with type 2 diabetes and high cardiovascular risk to insulin degludec or insulin glargine U-100, both titrated to a fasting plasma glucose target of 71-90 mg/dL (5).

Primary Cardiovascular Outcome

Degludec was non-inferior to glargine for 3-point MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke): hazard ratio 0.91 (95% CI 0.78-1.06, P<0.001 for non-inferiority). Cardiovascular safety means that any downstream sexual health benefits from better glycemic control are not offset by increased cardiac risk.

Hypoglycemia Reduction

Severe hypoglycemia occurred at a 40% lower rate with degludec versus glargine (rate ratio 0.60, 95% CI 0.48-0.76, P<0.001) (5). Nocturnal hypoglycemia, defined as confirmed symptomatic episodes between midnight and 6 a.m., was 53% lower with degludec. This is the most sexually relevant finding from DEVOTE: fewer middle-of-the-night glucose crises translate to less cortisol surging, less sleep disruption, and a more favorable hormonal environment for sexual function the following day.

HbA1c Similarity

Both agents achieved comparable HbA1c reductions at 2 years (approximately -1.0% from baseline in each arm), which means the hypoglycemia advantage of degludec was not purchased at the cost of worse glycemia. Lower hypoglycemia burden plus equivalent A1c is the specific combination that creates space for sexual health improvement.

Testosterone, Estradiol, and Insulin Therapy

Insulin Resistance and Androgen Suppression

Insulin resistance, which precedes and accompanies type 2 diabetes, independently lowers sex hormone-binding globulin (SHBG). Low SHBG reduces bioavailable testosterone even when total testosterone is in the normal range. A cross-sectional analysis from the European Male Ageing Study (N=3,369) found that SHBG was the single strongest predictor of bioavailable testosterone, more predictive than BMI or age (6).

Improving insulin sensitivity through any effective diabetes regimen tends to raise SHBG modestly. Degludec, by achieving tighter overnight glucose profiles, may contribute to that improvement, though head-to-head data specifically on SHBG trajectories comparing degludec to glargine have not been published.

Women, Estradiol, and Glycemic Variability

Glucose variability, measured as coefficient of variation or time-below-range, correlates with ovulatory dysfunction in premenopausal women with type 1 diabetes. A prospective cohort study (N=194, follow-up 12 months) published in Diabetes Care found that women with higher glycemic variability had lower estradiol levels in the follicular phase and higher rates of anovulation (7). Degludec's flatter pharmacokinetic profile may reduce glucose variability more than insulin glargine U-100, based on crossover clamp data showing a lower coefficient of variation for glucose-lowering effect (20% vs. 82% for NPH) (8).

Type 1 Diabetes: A Different Clinical Picture

In type 1 diabetes, the relationship between basal insulin choice and sexual function is driven almost entirely by hypoglycemia avoidance and glucose variability. A 52-week open-label trial (BEGIN BASAL 1, N=472) showed degludec reduced confirmed nocturnal hypoglycemia by 37% versus glargine U-100 in type 1 patients, with equivalent HbA1c (9). For a 35-year-old man with type 1 diabetes waking at 2 a.m. Three nights per week from hypoglycemia, reducing that to one night per week is a meaningful quality-of-life shift that could realistically translate to better sexual function.

Erectile Dysfunction in Diabetes: Where Does Basal Insulin Choice Actually Fit?

Erectile dysfunction in men with diabetes sits at the intersection of vascular, neurologic, hormonal, and psychological pathways. A clinician evaluating a diabetic man with ED should work through these layers before attributing the problem to, or expecting a solution from, any single insulin formulation:

Layer 1: Vascular (Most Common Cause)

Atherosclerosis reduces penile arterial flow. The internal pudendal artery has a smaller diameter than coronary vessels, so vascular ED often precedes angina. Cardiovascular risk factor control (LDL below 70 mg/dL, blood pressure below 130/80 mmHg, smoking cessation) is the primary intervention at this layer. DEVOTE's cardiovascular neutrality means degludec does not worsen this picture.

Layer 2: Neuropathic

Autonomic neuropathy of the cavernous nerves impairs the nitric oxide signal that initiates erection. The only intervention with meaningful evidence at this layer is sustained glycemic control over years. The DCCT (N=1,441, type 1 diabetes) showed that intensive glycemic control reduced the development of clinical neuropathy by 60% at 6.5 years (10). Degludec contributes to this layer by enabling tighter glycemia with less hypoglycemia.

Layer 3: Hormonal

Secondary hypogonadism occurs in approximately 25-40% of men with type 2 diabetes. Measurement of total testosterone, free testosterone (or calculated free testosterone), LH, and SHBG guides the decision on whether testosterone replacement therapy is indicated alongside optimized insulin therapy. Insulin degludec has no direct effect on this layer, but the reduction of nocturnal hypoglycemia may modestly protect nocturnal testosterone secretion, as outlined above.

Layer 4: Psychological and Relational

Fear of hypoglycemia is a documented psychological barrier to sexual activity in insulin-using patients. A 2019 survey-based study (N=312 adults on insulin therapy) found that 44% reported deliberately avoiding sexual activity on days when they perceived their glucose control to be unstable, citing fear of hypoglycemia during exertion (11). A basal insulin with a flatter, more predictable profile may reduce this avoidance behavior.

Practical Pharmacology: Why Degludec's Profile Matters for Sexual Health

Insulin degludec forms stable soluble multihexamers at the injection site, which disassemble slowly into monomers for absorption. This produces a half-life of approximately 25 hours and a duration of action exceeding 42 hours, compared with glargine U-100's approximately 12-hour half-life and 20-24 hour duration (8).

The clinical result is a glucose-lowering action that is far less dependent on precise injection timing. Patients who inject degludec 1-2 hours early or late maintain near-identical blood glucose profiles. That flexibility reduces the behavioral anxiety around insulin timing, which itself is a psychological stressor that can suppress sexual interest.

Dosing Flexibility Trial Evidence

The FLEX trial (N=687, type 1 and type 2 diabetes) randomly assigned patients to fixed daily dosing or forced variable timing (8-40 hours between injections). Glycemic control and hypoglycemia rates were statistically equivalent across arms (12). No comparable flexibility data exist for insulin glargine or detemir.

Day-to-Day Glucose Variability

A euglycemic clamp study (N=54) quantified within-person day-to-day variability in glucose-lowering effect: degludec's coefficient of variation was 20%, versus 82% for NPH insulin (8). Lower variability means fewer unpredicted low-glucose excursions, which is the most direct pharmacokinetic link between this insulin's profile and sexual health outcomes.

What Clinicians Should Actually Tell Patients

When a patient on Tresiba asks whether the drug is affecting their sexual function, the honest clinical answer involves three points:

First, degludec itself does not cause sexual dysfunction. No receptor, no metabolite, no mechanism links it directly to libido, erection, or orgasm.

Second, the patient's underlying diabetes, its duration, and its past glycemic control carry the primary causal burden. Neuropathy and vascular damage that accumulated over years of suboptimal control do not reverse quickly when insulin is optimized.

Third, degludec's reduction in nocturnal hypoglycemia is the most plausible pathway through which switching to this agent could, over months to years, create a hormonal and psychological environment more conducive to sexual function than what many patients experience on NPH or glargine U-100.

The 2023 Endocrine Society Clinical Practice Guideline on Male Hypogonadism states: "Clinicians should assess for reversible causes of androgen deficiency, including poorly controlled diabetes, before initiating testosterone therapy" (13). Optimizing basal insulin is a concrete step toward that reversal.

Screening and Monitoring Recommendations

Baseline Sexual Function Assessment

The ADA recommends annual screening for sexual dysfunction in all adults with diabetes using a validated tool. The International Index of Erectile Function (IIEF-5) and the Female Sexual Function Index (FSFI) are the most widely used instruments. Establishing a baseline score before and 6-12 months after starting degludec allows objective tracking.

Labs to Order Alongside Insulin Optimization

In men with diabetes and sexual dysfunction, a reasonable panel includes: fasting total testosterone (morning draw), SHBG, LH, FSH, prolactin, and HbA1c. If total testosterone is below 300 ng/dL on two separate morning draws, the Endocrine Society criteria for hypogonadism are met and specialist referral is appropriate (13).

In women, FSH, estradiol, and a menstrual cycle history provide the clearest picture. Thyroid function should be checked given the high co-prevalence of autoimmune thyroid disease in type 1 diabetes.

Continuous Glucose Monitoring as a Sexual Health Tool

Time-in-range (70-180 mg/dL) of at least 70% and time-below-range (<70 mg/dL) of <4% are the current ADA CGM targets (2). Reviewing CGM data specifically for overnight patterns (midnight to 6 a.m.) in a patient with sexual dysfunction gives the clinician an actionable picture. If overnight time-below-range exceeds 4%, basal dose reduction or a switch to degludec for its flatter pharmacokinetics is a rational intervention step.